United States Pre-Exposure Prophylaxis (PrEP) Market to Grow with a CAGR of 7.84% through 2028
Advancements in pharmaceutical
sector and improvements in healthcare infrastructure is expected to drive the United
States Pre-Exposure Prophylaxis (PrEP) Market growth in the forecast period,
2024-2028.
According to
TechSci Research report, “United States Pre-Exposure Prophylaxis
(PrEP) Market –Industry Size, Share, Trends, Competition Forecast &
Opportunities, 2018-2028F”, the United States Pre-Exposure Prophylaxis
(PrEP) Market stood at USD 280.51 Million
in 2022 and is anticipated to project steady growth in the forecast
period with a CAGR of 7.84% through 2028. The growth of the United States
Pre-Exposure Prophylaxis (PrEP) market is driven by several factors. Prevalent
factors include the increasing incidence of HIV infections, growing awareness
about PrEP, and government initiatives aimed at promoting its use.
Moreover,
improved healthcare infrastructure and accessibility of PrEP drugs also
contribute to the market growth. Advancements in medical research and the
development of more efficient PrEP drugs fuel the expansion of the market.
The United
States Pre-Exposure Prophylaxis (PrEP) Market is a dynamic and constantly
evolving landscape that encompasses the entire ecosystem associated with the
use of PrEP medications in the prevention of HIV infection across the United
States. PrEP, a revolutionary approach, involves the use of drugs taken by
individuals who do not have HIV but are at very high risk of contracting the
virus. This innovative preventive measure has gained significant acceptance and
usage, leading to a growing market that spans various sectors.
The market for
Pre-Exposure Prophylaxis (PrEP) medications goes beyond the manufacturing,
distribution, and sales aspects. It also encompasses the provision of
comprehensive healthcare services to ensure the effective administration of
PrEP. These services include regular monitoring, counseling, and testing to
support the well-being of individuals using PrEP. The collaborative efforts of
healthcare providers, pharmaceutical companies, and public health organizations
play a crucial role in expanding access to PrEP and reaching high-risk
communities. Moreover, the United States PrEP market is characterized by a
continuous stream of advancements and innovations. Ongoing research and
clinical trials aim to explore new formulations, delivery methods, and
combination therapies. These efforts are driven by the goal of enhancing the
efficacy and convenience of PrEP medications. By constantly pushing the
boundaries of what is possible in HIV prevention, the market remains at the
forefront of the fight against this global epidemic, ensuring that progress is
relentless and impactful.
The United
States Pre-Exposure Prophylaxis (PrEP) Market is a multifaceted arena that
encompasses a wide range of activities, from the development and production of
PrEP medications to the implementation of comprehensive healthcare services. It
represents a collective effort by various stakeholders to combat HIV and
improve the lives of individuals at risk, ultimately working towards a future
where new infections are significantly reduced, and the impact of HIV is
minimized. The dedication and innovation within this market play a vital role
in shaping the landscape of HIV prevention, paving the way for a healthier and
brighter future for all individuals affected by this disease.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on "UnitedStates Pre-Exposure Prophylaxis (PrEP) Market.”
The United
States Pre-Exposure Prophylaxis (PrEP) Market is segmented into drug, route of
administration, regional distribution, and company.
Based on route
of administration, the United States Pre-Exposure Prophylaxis (PrEP) market is
poised to witness a significant boost in the coming years, primarily driven by
the oral route of administration. Oral PrEP entails the regular intake of
antiviral medications by individuals at high risk of HIV infection, serving as
a preventive measure to curb the spread of the virus. This method has
demonstrated remarkable effectiveness and garnered high compliance rates, owing
to its undeniable convenience and ease of use. Moreover, it has already
received approval from the FDA, positioning it as a trusted and reliable option
among healthcare providers and patients alike.
With the rising
awareness about HIV prevention and the pressing need for effective strategies,
the PrEP market in the United States is expected to experience substantial
growth and expansion in the foreseeable future. The availability of oral PrEP
not only offers a practical and accessible solution but also empowers
individuals to take control of their health by reducing the risk of HIV
transmission. As more research and development efforts continue to refine and
innovate PrEP formulations, the market is likely to witness further
advancements, ensuring enhanced prevention and improved outcomes for
individuals at risk.
Based on region,
the market for Pre-Exposure Prophylaxis (PrEP) in the United States is
predominantly dominated by the Northeast region for several compelling reasons.
Firstly, the Northeast encompasses highly populous states, such as New York and
Massachusetts, which are home to bustling urban centers where the prevalence of
HIV and associated risk behaviors tend to be higher. This concentration of
population creates a greater demand for PrEP services and resources. In
addition to the higher prevalence of HIV, the Northeast region has also
established a strong and effective public health infrastructure. This includes
comprehensive awareness campaigns that aim to educate individuals about the
importance of HIV prevention and the availability of PrEP. With these campaigns
in place, individuals are more likely to understand the benefits of PrEP and
seek out the necessary services.
Furthermore, the
Northeast region benefits from robust healthcare policies that support the
affordability and accessibility of PrEP. Many states in this region have
implemented measures to ensure that PrEP is affordable for individuals,
regardless of their financial situation. Additionally, these states have
streamlined access to PrEP services, making it easier for individuals to obtain
and adhere to the medication regimen. Overall, the combination of a higher
prevalence of HIV, a strong public health infrastructure, and supportive
healthcare policies has led to the dominance of the Northeast region in the
PrEP market. These factors have contributed to increased usage and availability
of PrEP, ultimately helping to prevent new HIV infections and improve public
health outcomes.
Major companies
operating in the United States Pre-Exposure Prophylaxis (PrEP) Market are:
- Gilead Sciences, Inc.
- Teva Pharmaceuticals USA, Inc.
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
- Genentech, Inc.
Download Free Sample Report
Customers can
also request 10% free customization on this report.
“The future of
the United States Pre-Exposure Prophylaxis (PrEP) market appears exceptionally
promising. As awareness and acceptance of PrEP as a preventive measure against
HIV continue to rise, there is a projected increase in the demand for these
medications. This surge in demand is further bolstered by the unwavering
support from governmental bodies in their efforts to curb HIV infections.
Moreover, advancements in drug development and the imminent approval of more
affordable generic versions are expected to propel the market forward. While
the future of the United States PrEP market holds great promise, it is
essential to continue addressing these challenges through comprehensive
strategies and collaborations to ensure optimal outcomes for HIV prevention and
control efforts.,” said Mr. Karan Chechi, Research Director with TechSci
Research, a research-based management consulting firm.
“United
States Pre-Exposure Prophylaxis (PrEP) Market By
Drug Type (Truvada, Descovy), By Route of Administration (Oral, Topical), By
Region, Competition, Forecast and& Opportunities, 2018-2028F”, has evaluated
the future growth potential of United States Pre-Exposure Prophylaxis (PrEP)
Market and provides statistics & information on market size, structure and
future market growth. The report intends to provide cutting-edge market
intelligence and help decision-makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in United States Pre-Exposure
Prophylaxis (PrEP) Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com